HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytyc Together with Hologic: There's a Certain Logic

Executive Summary

What do you get when you cross a women's health company that sells screening and diagnostic imaging technologies to hospitals and radiologists, with a women's health company that sells diagnostics and therapeutic devices to Ob-Gyns? A single company capable of selling goods and services across the entire continuum of care, according to Rob Cascella, president & COO of Hologic, who thus revealed the reasoning behind the $6.5 billion proposed merger of Hologic with Cytyc.

You may also be interested in...



Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover a new GAO report that ups the pressure on the medical imaging market; Cordis Corp.'s suspension of its PFO closure device program; Atritech's PMA for stroke prevention; Zimmer's acquisition of Abbott Spine; and the US market for contraception devices and procedures.

Women's Health: Numbers Too Big To Ignore

The women's health opportunity in the US is $2.75 billion on an annual basis, and it's growing at a compounded rate of 16% per year. Looking forward, demographics, the aging of the population, and technological innovations will continue to fuel growth. New technologies promise to cause one particular category in women's health to blossom; the treatment of uterine fibroids. According to "Women's Health: US Markets for Benign Uterine Condition Management Products," a report recently published by the Medtech Insight division of Windhover Information Inc., the number of fibroid treatments is expected to increase at a compound annual rate of 21.3%. The report also discusses the markets for the treatment of menorrhagia and endometriosis.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel